Blair William & Co. IL Decreases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Blair William & Co. IL reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 38.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 1,255 shares of the biopharmaceutical company's stock after selling 788 shares during the period. Blair William & Co. IL's holdings in Regeneron Pharmaceuticals were worth $894,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Willner & Heller LLC lifted its stake in shares of Regeneron Pharmaceuticals by 3.9% in the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock worth $284,000 after acquiring an additional 15 shares during the period. OLD Second National Bank of Aurora lifted its position in Regeneron Pharmaceuticals by 0.5% in the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock valued at $2,025,000 after purchasing an additional 15 shares during the period. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares in the last quarter. TD Private Client Wealth LLC increased its position in Regeneron Pharmaceuticals by 9.6% during the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after purchasing an additional 15 shares during the period. Finally, Manchester Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 12.6% in the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock valued at $115,000 after buying an additional 18 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Piper Sandler reduced their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a report on Monday, January 27th. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Sanford C. Bernstein reduced their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. Finally, Robert W. Baird lowered their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $966.88.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded down $15.97 during midday trading on Tuesday, hitting $556.81. 1,146,823 shares of the company's stock were exchanged, compared to its average volume of 695,246. Regeneron Pharmaceuticals, Inc. has a 12 month low of $546.36 and a 12 month high of $1,211.20. The firm has a market capitalization of $60.87 billion, a PE ratio of 14.55, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The company's 50 day moving average price is $669.26 and its 200 day moving average price is $766.90. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company posted $11.86 EPS. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.63%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.